Imac | 10-Q: FY2025 Q3 Revenue: USD 21.22 K

Revenue: As of FY2025 Q3, the actual value is USD 21.22 K.

EPS: As of FY2025 Q3, the actual value is USD -1.15.

EBIT: As of FY2025 Q3, the actual value is USD -2.135 M.

For the three months ended September 30, 2025, IMAC Holdings, Inc. reported net revenue of $0.02 million, compared to $0.06 million for the same period in 2024.
For the nine months ended September 30, 2025, net revenue was $0.02 million, compared to $0.07 million for the same period in 2024.

The company reported a net loss of $3.1 million for the three months ended September 30, 2025, compared to a net loss of $2.2 million for the same period in 2024.
For the nine months ended September 30, 2025, the net loss was $7.4 million, compared to $4.0 million for the same period in 2024.
Operating expenses for the three months ended September 30, 2025, were $2.5 million, up from $1.9 million in the same period in 2024.
Operating expenses for the nine months ended September 30, 2025, were $6.4 million, compared to $3.7 million for the same period in 2024.

Net cash used in operating activities for the nine months ended September 30, 2025, was $3.8 million, compared to $2.0 million for the same period in 2024.
Net cash provided by financing activities during the nine months ended September 30, 2025, was $3.3 million, primarily from the sale of common stock and issuance of promissory notes.

The company recognized an impairment loss of $0.75 million on laboratory equipment during the three months ended September 30, 2025.

Core Business Focus: IMAC Holdings, Inc. plans to focus on its precision medicine in cancer treatment, leveraging its RPPA technology platform to support oncology clinical treatment decisions and biopharmaceutical drug development.
Non-Core Business: The company has discontinued operations related to patient care at all locations as of December 31, 2023, and is focusing on its laboratory capabilities acquired from Theralink Technologies, Inc.
Priority: The company aims to raise additional capital to fund future operations and mitigate substantial doubt about its ability to continue as a going concern.

BACK